Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
76.27 K
Value Traded
6.71 M
Short % Float
2.1%
Days to Cover
1.6
+4.14%Week
-38.22%1 Month
-2.5%3 Month
-2.5%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
495.84 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
400.47 M
Total Shares
31.78 M
Float Shares
22.59 M
Insiders
28.93%
Institutions
20.63%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
BLSM Catalyst Timeline
Dated clinical, regulatory and corporate events for BlossomHill Therapeutics, Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for BlossomHill Therapeutics, Inc. Common Stock
26Total events
10Upcoming
1Tier-1 (high impact)
2026 to 2028Coverage
Upcoming catalysts 2
Event history 12
▲Preclinical PoCBH-501284Preclinical
Preclinical data for BH-501284 presented at AACR Conference on Pancreatic Cancer
KRAS-mutant cancers (pancreatic, lung, colorectal)source ↗
●Quarterly UpdateCorporate
BlossomHill Therapeutics reports second quarter 2026 financial results
▲Oral PresentationBH-30643Presentation
Updated Phase 1/2 SOLARA data presented in mini-oral presentation at IASLC 2026 World Conference on Lung Cancer
EGFR C797S-positive NSCLCsource ↗
▲Fast Track DesignationBH-30643Designation
FDA granted Fast Track designation to BH-30643
advanced or metastatic EGFR C797S-positive non-small cell lung cancer (NSCLC) after prior treatment with a third-generation EGFR TKIsource ↗
●Oral PresentationBH-30643Presentation
Preliminary BH-30643 Phase 1 dose escalation data presented at ASCO 2026
EGFR-mutant NSCLCsource ↗
●Oral PresentationBH-30236Presentation
Initial BH-30236 Phase 1/1b clinical data presented at EHA 2026 Congress
R/R AML and HR-MDSsource ↗
▲Additional DataBH-30643Clinical Data
Updated SOLARA data: 45% ORR and 88% DCR in EGFR C797S-positive NSCLC
EGFR C797S-positive NSCLCsource ↗
▲Safety Data UpdateBH-30643Clinical Data
Favorable safety profile reported at 40/50/60 mg BID expansion doses
EGFR-mutant NSCLCsource ↗
●Preclinical PoCBH-501284Preclinical
First preclinical data for pan-KRAS inhibitor BH-501284 presented at AACR 2026
KRAS-mutant tumorssource ↗
▲Oral PresentationBH-30643Presentation
Additional BH-30643 follow-up data presented at IASLC 2026 World Conference on Lung Cancer
EGFR-mutant NSCLCsource ↗
▲Additional DataBH-30643Clinical Data
Additional BH-30643 follow-up data presented at IASLC 2026 World Conference on Lung Cancer
advanced or metastatic EGFR-mutant NSCLCsource ↗
Past FDA Catalysts and PDUFA Decisions
How BLSM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-15 | BH-30643 | Phase 1/2 data presentation | Phase 1/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BLSM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BH-30643 Fast Track | EGFR C797S-positive NSCLC | Phase 1/2 | 2026-09-15 | objective response rate: 45%; disease control rate: 88%; patients on treatment: 63%; median follow up: 6.9 monthsRead More | BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Chen BihuaDirector, 10% Owner | Buy | 312,500 3,614,034 held | $16.00 | 08/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BLSM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BLSM for Q2 2026. | ||||
BLSM Institutional Ownership Trends
BLSM Short Interest
Shares sold short, counted twice a month.
2.1%
Short % of Float
of tradable shares sold short
473.8K
Shares Sold Short
+244.4% vs prior count
1.6 Low
Days to Cover
trading days of normal volume to buy every short share back
291.7K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BLSM ranks across every disease it competes in
Competitive Position is a premium feature
See how BLSM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBLSM News
-BLSM
Oct 22, 2026▲ +8.3%today
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
BlossomHill Therapeutics announced a collaboration with Foundation Medicine to develop a companion diagnostic assay for the EGFR C797S mutation in non-small cell lung cancer. This partnership will support the ongoing Phase 1/2 SOLARA trial of BH-30643, a novel treatment targeting this resistance mutation. The collaboration aims to validate the diagnostic assay to guide BH-30643's development.
Read more →-BLSM
Sep 28, 2026▲ +8.1%on this news
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
BlossomHill Therapeutics presented promising preclinical data on BH-501284, a novel pan-KRAS inhibitor, at the AACR Conference. The data indicate that BH-501284 achieves prolonged target engagement and significant antitumor activity in various KRAS-mutant cancer models. The company aims for an IND submission in Q1 2027, highlighting the potential of this innovative therapy.
Read more →-BLSM
Sep 18, 2026BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
BlossomHill Therapeutics reported strong financial results for Q2 2026, highlighted by a successful IPO that raised $168.3 million. The company announced FDA Fast Track designation for its drug BH-30643, aimed at treating advanced EGFR C797S-positive NSCLC. Preliminary trial results show promising efficacy, and the company is preparing for key upcoming milestones in its clinical development pipeline.
Read more →-BLSM
Sep 15, 2026BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
BlossomHill Therapeutics presented updated data from the Phase 1/2 SOLARA trial, highlighting the efficacy of BH-30643 in treating EGFR C797S-positive NSCLC. The trial reported a 45% objective response rate and an 88% disease control rate among patients resistant to prior EGFR inhibitors. BH-30643 also demonstrated a favorable safety profile, with minimal treatment-related adverse events. The company plans to advance to a Phase 2 trial in 2027 following FDA Fast Track designation.
Read more →-BLSM
Sep 3, 2026BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
BlossomHill Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two significant conferences: the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference. Key presentations will be made by Dr. Geoff Oxnard and Dr. Jean Cui. The company aims to showcase its innovative cancer treatments and engage with investors.
Read more →-BLSM
Sep 1, 2026BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
BlossomHill Therapeutics will present updated data from the Phase 1/2 SOLARA trial for BH-30643, an investigational treatment for EGFR-mutant NSCLC, at the 2026 World Conference on Lung Cancer. The data will focus on the drug's anti-tumor activity against secondary EGFR resistance mutations, particularly C797S. This presentation is significant as there are currently no approved therapies for patients with this mutation.
Read more →-BLSM
Aug 18, 2026BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
BlossomHill Therapeutics has received FDA Fast Track designation for its investigational drug BH-30643, aimed at treating advanced EGFR C797S-positive non-small cell lung cancer. This designation acknowledges the drug's potential to meet significant unmet medical needs. BH-30643 is currently being evaluated in a global Phase 1/2 clinical trial, SOLARA, across multiple sites. The Fast Track status may allow for more frequent interactions with the FDA and eligibility for accelerated approval.
Read more →-BLSM
Aug 7, 2026BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
BlossomHill Therapeutics has announced the pricing of its upsized initial public offering, offering 9,375,000 shares at $16.00 each, aiming to raise $150 million. The shares will begin trading on Nasdaq under the ticker 'BLSM' on August 7, 2026. The offering is set to close on August 10, 2026, pending customary conditions.
Read more →-BLSM
Jun 11, 2026BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026
BlossomHill Therapeutics presented initial clinical data on BH-30236, a novel CLK inhibitor, at the EHA 2026 Congress. The drug showed promising anti-leukemic activity in patients with relapsed or refractory AML and higher-risk MDS, particularly in those resistant to prior venetoclax therapy. The trial results indicate a favorable safety profile and potential for further development.
Read more →-BLSM
May 21, 2026BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting
BlossomHill Therapeutics is set to present preliminary results from the Phase 1 dose escalation/backfill cohorts of the SOLARA trial for BH-30643, an OMNI-EGFR inhibitor, at the 2026 ASCO Annual Meeting. The data indicate promising clinical activity in advanced EGFR-mutant NSCLC, particularly in patients with challenging mutations. The ongoing Phase 1 dose expansion aims to determine the recommended Phase 2 dose.
Read more →-BLSM
May 20, 2026BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid
BlossomHill Therapeutics has expanded its Board of Directors with the appointments of Dr. Sheila Gujrathi and John Schmid. Both appointees bring extensive experience in biopharmaceuticals, which is expected to support the company's growth in developing next-generation cancer medicines. The company is advancing multiple precision oncology programs and aims to improve patient outcomes.
Read more →About BlossomHill Therapeutics, Inc. Common Stock
Headquarters10255 SCIENCE CENTER DRIVE, SAN DIEGO, CA
BIOPHARMAWATCH ELITE PLUS
Trade the next BLSM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime